⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMLX News
Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
businesswire.com
AMLX
Form 8-K
sec.gov
AMLX
Form 8-K
sec.gov
AMLX
Form 8-K
sec.gov
AMLX
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
businesswire.com
AMLX
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
businesswire.com
AMLX
Form 8-K
sec.gov
AMLX
Form 8-K
sec.gov
AMLX
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
businesswire.com
AMLX
Form 8-K
sec.gov
AMLX